Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc
ClinicalTrials.gov Identifier:
NCT00554827
First received: November 5, 2007
Last updated: May 8, 2013
Last verified: May 2013

November 5, 2007
May 8, 2013
August 2007
January 2012   (final data collection date for primary outcome measure)
Determine an Effective and Well-tolerated Dose and Schedule of Pralatrexate with Vitamin B12 and Folic Acid Supplementation for Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma (CTCL) [ Time Frame: Assessed at the end of every even-numbered cycle (every 8 weeks) for the first 6 months, then every 4 cycles (16 weeks) ] [ Designated as safety issue: Yes ]
To determine an effective and well-tolerated dose and schedule of pralatrexate with vitamin B12 and folic acid supplementation that can be administered safely to patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). [ Time Frame: Study duration ]
Complete list of historical versions of study NCT00554827 on ClinicalTrials.gov Archive Site
Characterize the Safety Profile of Pralatrexate in Patients with Relapsed or Refractory CTCL. [ Time Frame: Assessed at all study visits: weekly while on treatment and at safety follow-up (35 +/- 5 days post-last dose) or early termination visit (at time of withdrawal) ] [ Designated as safety issue: Yes ]
To characterize the safety profile of pralatrexate in this group of patients. [ Time Frame: Study duration ]
Not Provided
Not Provided
 
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
A Phase 1, Open-label Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

This study is being conducted to identify how much and how often pralatrexate, given with vitamin B12 and folic acid, can be given safely to patients with cutaneous T-cell lymphoma (CTCL) that has relapsed (returned after responding to previous treatment) or is refractory (has not responded to previous treatment). It is also being conducted to get information on whether or not pralatrexate is effective in treating relapsed or refractory CTCL.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Cutaneous T-cell Lymphoma
  • Drug: Pralatrexate Injection

    Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).

    Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or 4 weeks (depending on cohort), with 1 week of rest.

    Other Names:
    • FOLOTYN
    • PDX
    • Pralatrexate
    • (RS)-10-propargyl-10-deazaaminopterin
  • Dietary Supplement: Vitamin B12

    1 mg intramuscular injection

    Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.

    Administered every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.

    Other Name: Cyanocobalamin
  • Dietary Supplement: Folic Acid

    1 mg orally

    Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.

    Administered daily throughout the study and for at least 30 days after last dose of pralatrexate.

    Other Names:
    • Vitamin B9
    • Folate
    • Folacin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
55
February 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmed relapsed or refractory cutaneous T-cell lymphoma (CTCL):

    1. Mycosis fungoides Stage IB or higher
    2. Sézary syndrome
    3. Primary cutaneous anaplastic large cell
  • No curative treatment options.
  • Progression of disease (PD) or relapse of disease after at least 1 previous systemic therapy, PD after last prior treatment regimen, and recovered from the toxic effects of prior therapy.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
  • Life expectancy ≥ 3 months.
  • Adequate blood, liver, and kidney function as determined by laboratory tests.
  • Methylmalonic acide (MMA) serum concentration < 200 nmol/L and homocysteine (Hcy) concentration < 10 μmol/L at screening, or receipt of 1 mg daily oral folic acid for at least 10 days prior to the planned start of pralatrexate and 1 mg intramuscular vitamin B12 within 10 weeks of the planned start of pralatrexate.
  • Women of childbearing potential must use a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last dose of pralatrexate and must have a negative serum pregnancy test within 14 days prior to the first day of study treatment. Serum pregnancy test not required for patients who are postmenopausal (greater than 12 months since last menses) or are surgically sterilized.
  • Women who are breastfeeding.
  • Men who are not surgically sterile must use a medically acceptable contraceptive regimen from start of pralatrexate until at least 90 days after the last administration of pralatrexate.
  • Written informed consent and privacy authorization.

Exclusion Criteria:

  • Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 5 years. Patients with other prior malignancies < 5 years before study entry may be enrolled if treatment resulted in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease.
  • Congestive heart failure Class III/IV per the New York Heart Association Heart Failure Guidelines.
  • Uncontrolled hypertension.
  • Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of <100 mm3 or detectable viral load within the past 3 months, and is receiving combination anti-retroviral therapy.
  • Symptomatic central nervous system metastases or lesions for which treatment is required.
  • Active uncontrolled infection, underlying medical condition that would impair ability to receive protocol treatment.
  • Major surgery within 2 weeks of planned start of treatment.
  • Receipt of any conventional chemotherapy or radiation therapy (RT) encompassing >10% of bone marrow within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the study.
  • Receipt of systemic corticosteroids within 3 weeks of study treatment, unless on a continuous dose of ≤10 mg/day of prednisone for at least 1 month.
  • Initiation of or change in dosage of topical corticosteroids within 3 weeks of study treatment (topical steroid use within 3 weeks is allowed if strength/use has been stable for at least 1 month; topical corticosteroids cannot be started during the study).
  • Use of investigational drugs, biologics, or devices within 4 weeks prior to study treatment or planned use during the study.
  • Receipt of a monoclonal antibody within 3 months without evidence of progression.
  • Use of oral retinoids within 4 weeks of study treatment or high-dose vitamin A.
  • Previous exposure to pralatrexate, unless the patient was on this study, achieved a complete or partial response, and was taken off study treatment because of investigator decision, and subsequently experienced disease recurrence or progressive disease.
  • Re-entering patients: must not have received subsequent therapy for CTCL during the time off initial study treatment.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00554827
PDX-010
Not Provided
Spectrum Pharmaceuticals, Inc
Spectrum Pharmaceuticals, Inc
Not Provided
Study Director: Michael Saunders, MD Spectrum Pharmaceuticals, Inc
Spectrum Pharmaceuticals, Inc
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP